|
|
| | CW-3308 Basic information |
| | CW-3308 Chemical Properties |
| density | 1.436±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 10.703±0.40(predicted) |
| | CW-3308 Usage And Synthesis |
| Uses | CW-3308 is an orally effective PROTAC that selectively targets BRD9 and is expected to be used to inhibit synovial sarcoma, rhabdomyoma, and other BRD9-dependent human diseases. CW-3308 is composed of PROTAC target protein ligand Naphthyridin-Me-dimethoxybenzene-COOH (HY-159596) (red part), Linker 3-Azaspiro[5.5]undecane-9-methanol (HY-159598) (black part), E3 ubiquitin ligase ligand Thalidomide-methylpyrrolidine (HY-159597) (blue part), where the conjugate of E3 ubiquitin ligase ligand + linker is Thalidomide-pyrrolidine-C-azaspiro (HY-159599)[1]. | | References | [1] Wang C, et al. Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9. J Med Chem. 2024 Aug 22;67(16):14125-14154. DOI:10.1021/acs.jmedchem.4c00971 |
| | CW-3308 Preparation Products And Raw materials |
|